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Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with 
tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the BCR-
ABL1 fusion gene in peripheral white blood cells
1
. This analysis is based on reverse-transcription 
quantitative PCR (RT-qPCR) technology; however, the wide array of methods used worldwide has 
led to large variation in quantitative BCR-ABL1 measurements, which hamper inter-laboratory 
comparative studies
2,3
. It is now recognized that monitoring BCR-ABL1/control gene ratios on the 
International Scale (IS) is vital for the management of patients with CML
4
. Efforts to harmonize 
procedures to measure BCR-ABL1 fusion transcripts have included important investments in 
sample exchange programs to derive laboratory-specific conversion factors (CF); these efforts 
showed improvements in inter-laboratory concordance rates, but the process is laborious and 
limited due to the lack of a common set of reference samples that can be shared on a global scale. 
This requirement was recently addressed in part by the formulation and validation of the first World 
Health Organization (WHO) International Genetic Reference Panel for quantitation of BCR-ABL1 
by RT-qPCR
5
. The WHO primary standards consist of a 4-level panel of e14a2-positive lyophilized 
cell line dilutions. Each level has an assigned IS-value, which was obtained by repeated testing of 
each sample level in expert IS-standardized laboratories. Unfortunately, the stock of WHO primary 
standards is limited, and their accessibility has been restricted to manufacturers of testing kits or 
secondary reference standards. In this study, we aimed to develop and validate secondary reference 
materials calibrated to the IS through the WHO primary standards in order to facilitate 
standardization of molecular monitoring in Latin America.  
The study design comprised five principal steps as illustrated in Supplementary Figure 1. 
The study was conducted by a single reference laboratory (rLAB, Buenos Aires, Argentina), which 
initially obtained a CF to the IS by sample exchange with the reference laboratory in Adelaide in 
2010. To ensure consistent performance of rLAB analytical system (MolecularMD, OR, USA), we 
included 2 quality control (QC) RNA-samples with a high and low BCR-ABL1 level in each run 
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(Supplementary Table 1 and Supplementary Material and Method, Section 1). To further validate 
our method prior to calibration of secondary reference materials (see below), we derived a CF by 
using WHO primary standards (NIBSC code 09/138) from the United Kingdom National Institute 
for Biological Standards and Control (Potters Bar, UK). The antilog of the estimated mean bias (-
0.152) was designated as the conversion factor (CF=0.7) for the rLAB method (Supplementary 
Table 2), very close (i.e. well within 2 fold) to the value of 0.45 obtained by sample exchange 3 
years previously. 
Previous local exploratory investigation indicated us that RT-qPCR methodologies 
harmonization was necessary since the tests were inadequately comparable, considering that the 
three acceptance criteria proposed by Muller et al.
6 
were not satisfied (Supplementary Tables 3 and 
4). To this aim we established and validated five batches of cellular calibrators produced by serial 
dilution of the Ph-positive cell line K562 in the Ph-negative cell line HL-60. Formulations were 
planned to target IS% ratios close to each of the established TKI clinical response criteria
7,8,9
, that 
is, between 10%, 1%, 0.1% (MR
3.0
), 0.01% (MR
4.0
). An additional dilution (0.001%, MR
5.0
) was 
included in order to assess the limit of detection of the methods and was not considered for the 
estimation of the CF (Figure 1). Cell mixes were stabilized by lyophilisation (Supplementary Figure 
2A); assignment of IS%-values to each batch and level of these secondary standards was achieved 
by repeated testing of randomly picked ampoules on 4 non-consecutive days (Figure 1 and 
Supplementary Material and Method, Section 2). Stability studies of the freeze-dried cells, showed 
no significant changes in the BCR-ABL1/ABL1 ratio over time at different temperatures up to six 
months (Supplementary Figure 2B). The calibrated secondary reference standards were distributed 
to 18 testing laboratories from 7 countries in Latin America. Each laboratory followed the 
calibrators’ instructions for use, which recommended 4 independent runs on different days for the 
two panels (Supplementary Materials and Methods, Section 3). A total of 1,312 RT-qPCR positive 
results were generated; mean raw percentage ratios generated in all laboratories were consistent 
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with a 10-fold serial dilution and were linear for the first 4 levels (Supplementary Figure 3); prior to 
CF calculation, in order to assess if bias was uniform across the BCR-ABL1 expression range, 
Bland-Altman analysis
10
 was performed for each assay (Supplementary Material and Method, 
Section 4). All the assays showed a uniform bias, indicating that a valid CF could be calculated for 
these methods (Supplementary Table 5). All raw %ratios measured within the linear range of each 
local RT-qPCR method were compared against a single set of reference values, the nominal IS%-
ratios. Laboratory-specific CFs were calculated by Bland–Altman method10 (Supplementary Table 
5). The relative mean bias ranged from -0.45-fold to +0.25-fold in distinct laboratories (Figure 2A); 
after correction of the individual raw percent ratios with the laboratory specific CF, the residual 
mean bias was null (Figure 2B). In addition, raw BCR-ABL1/ABL1 %ratios generated in each 
laboratory were used to assess the corresponding level-specific coefficient of variation (CV): 
between 8% and 58% (12 out of 18 laboratories with an average CV less than 30%). As expected, 
BCR-ABL1 was inconsistently detected below the linear quantitative detection range of the RT-
qPCR method in the lowest positive samples (fifth calibrator); for the 10 laboratories that tested the 
fifth calibrator, the overall BCR-ABL1 detection rate ranged from 12.5% to 100%. In total, eight 
out of ten laboratories could reproducibly detect BCR-ABL1 in level-5 samples (Supplementary 
Table 5). Interestingly, 5 laboratories had previous standardization, thus we could compare the new 
CF to the laboratory’s current CF; when no methodology modifications were introduced since the 
time of the last calibration we obtained highly concordant CFs (Supplementary Table 6). 
For appropriate clinical decisions, we need to judge agreement between the methods after 
IS conversion; to this aim, we interchanged 41 whole blood samples (divided into two parts) from 
CML patients with Lab#09. The concordance in MR
IS
 between the reference method and the 
external laboratory was 88% after conversion (36 out of 41 samples were in the same MR category) 
(Figure 2C). This result underlines the importance of conversion to the IS, given that, after 
harmonization we were able to halve the number of discordant data (from 9 to 5 cases). 
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In the present study, we show that secondary reference biological calibrators anchored to 
the WHO primary standards can decrease inter-laboratory variability. Our results, together with 
those recently reported by Cross et al.
11
, substantiate the objective initially set during the 
establishment of the WHO primary standards, that is, to facilitate worldwide diffusion of the IS. For 
the first time in Latin America, this study provides a platform on which to assess the performance of 
distinct clinical BCR-ABL1 tests and confirm the utility of secondary reference materials to further 
improve IS accuracy and inter-laboratory precision. This effort will continue in the future by 
providing secondary reference material to the centres involved in this project and potential new 
participants; moreover, due to its higher precision and absolute quantification capability, we are 
evaluating to include digital PCR as the calibration method for the future. 
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Figure legends 
Figure 1: Study design for the nominal IS% value assignment and BCR-ABL1 testing by 
participating laboratories. 
Figure 2: (A) Relative difference between nominal and measured IS% ratios for all calibrator levels 
combined (black circle). (B) Residual difference after CF-conversion. Error bars show 95% LOA 
interval. (C) Correlation graph. Comparison of IS%-ratios from 41 whole blood samples, 
interchanged between the rLAB and local Lab#09. Grey-coloured squares represent the 
concordance area for the assignment of the molecular response. Black points; concordant results. 
Red points; discordant results. Black line; equality line. 
©    2016 Macmillan Publishers Limited. All rights reserved.
Figure 1
©    2016 Macmillan Publishers Limited. All rights reserved.
AB
C
Figure 2
©    2016 Macmillan Publishers Limited. All rights reserved.
